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httpcense.Abstract Setting: It is important to identify manifestations of alpha1-antitrypsin deﬁciency
(A1ATD) in bronchiectasis to improve care and outcome in these patients.
Objective: To clinically evaluate A1ATD in patients with non cystic ﬁbrosis bronchiectasis.
Material and methods: Patients with non cystic ﬁbrosis bronchiectasis were diagnosed on the
basis of clinical and radiological ﬁndings. They fulﬁlled the inclusion criteria and divided into group
(A) bronchiectasis with hyperinﬂation (30 cases) and group (B) bronchiectasis without hyperinﬂa-
tion (30 cases). All patients were subjected to history taking, pulmonary function tests, and quan-
titative measurements of serum A1AT by radio-immunoassay.
Results: Mean age of both groups was (50 ± 8.58) and (36.87 ± 11.35) respectively (p value
0.0001). There were signiﬁcant differences in gender distribution (p= 0.006), and smoking history
(p value 0.0001). Hemoptysis was presented in 12 cases (40%), and 20 cases (66.67%) in both groups
respectively (p= 0.04). Dyspnea was presented in 27 cases (90%) and 19 cases (63%) for groups A
and B (p= 0.02). There were no signiﬁcant differences in sinusitis, hepatological symptoms, club-
bing and family history. There were signiﬁcant differences in cyanosis, edema of lower limb, chest
wheeze, radiological evaluation and spirometeric parameters (p value of 0.01, 0.004, 0.001, 0.001,
0.001, respectively). Three cases (5%) of A1ATD were diagnosed among all patients one case
(1.5%) in group (A) of MZ allele and two brother cases (3.5%) in group (B) of SZ allele were with-
out statistical signiﬁcance.454856.
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312 M.S. Badawy et al.Conclusion: A1ATD can be found in patients with bronchiectasis with or without concomitant
hyperinﬂation. Inheritance could inﬂuencean individual’s riskofA1ATDfordevelopingbronchiectasis.
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1. Comprehensive history: age, gender, smoking history, tobacco
exposure
Respiratory symptoms:
Age of onset of symptoms
Cough, expectoration, and dyspnea (its grade, duration)
Frequency of acute exacerbations in last year
Symptoms of sinusitis
Associated diseases: hepatological, dermatological symptoms
Family history of similar disease
2. Clinical examination
General examination: focused on cyanosis, lower limb edema,
clubbing of ﬁngers
Chest examination: inspection, palpation, percussion,
auscultation
Abdominal examination: focused on hepatomegaly
3. Radiological evaluation:
chest-X-ray (postero-anterior, lateral view)
High resolution C-T chest
4. Pulmonary function tests
They were performed with a spirometer of computer processing
(Jaeger Master Screen Diﬀusion, Viasys Healthcare, Gmbh,
Hochberg, Germany). Age, height and weight of the subjects were
entered in the spirometer. The spirometer gives two values: one is
the expected value and the other is the actual value. The expected
values are based on height, age and weight of the subjects. FVC,
FEV1, FEV1/FVC, were measured
Bronchodilator reversibility: The subjects received nebulized short
acting B2 agonist (2.5 mg salbutamol) then the test repeated after
10–15 min (the patients did not receive bronchodilators in the past
12 h). The percentage improvement in FEV1 can be calculated as
follows: (Postbronchodilator FEV1-Prebronchodilator FEV1)/
prebronchodilator FEV1 X 100. A positive response to
bronchodilators is an increase in FEV1 from baseline that is
more than 200 ml and more than 12% of the pre-bronchodilator
value
Technique of pulmonary function tests: The actual values (FVC,
FEV1, FEV1/FVC) are based on the maximal inspiration and
expiration of the subjects. The pulmonary function test was
conducted by seating the subject comfortably in a chair.
Sterilization of the mouthpiece was done before use. The subjects
were asked to perform maximum inspiration followed by maximal
exhalation. Three tests were performed and the subjects were
assisted to improve their eﬀorts. The best of the three performances
of FVC, FEV1, FEV1/FVC were taken [14]
5. Arterial blood gases
ABL 700 SERIES. Arterial blood gas analysis refers to the
measurement of PH and the partial pressures of oxygen (O2), SO2,
carbon dioxide (CO2) in arterial blood and HCO3.
Technique of arterial blood gases: Place the patient’s hand in
the supine position with the wrist extended. Identify the radial artery
by palpating the pulse; choose a site where the pulse is prominent.
Clean the sampling site with an alcohol wipe and wait until dry.
Then insert the needle slowly. When the needle is in the artery a ﬂash
of pulsatile blood will appear and obtain at least 3 ml of blood before
withdrawing the needle.Introduction
Alpha-1-antitrypsin deﬁciency (AATD) is a genetic disorder
characterizedby low serum levels ofAAT.Lowplasmaandalve-
olar concentrations in humanbody predispose individuals to the
development of early-onset pulmonary disease, most commonly
bronchiectasis, emphysemaandCOPD [1]. Life threatening liver
disease is another possible consequence ofAATD.Although it is
one of the most common inherited conditions, it affects about 1
in 2000–5000 individuals – it is under diagnosed [2].
The incidence and prevalence of bronchiectasis are generally
not well known and are underestimated in developing countries
[3]. Although the prevalence once declined over the past years
in societies with high socioeconomic status, probably due to
the development of preventive medicine, especially childhood
immunizations, and improvement of the living conditions and
widespread use of antibiotics, nowadays bronchiectasis has
been recognized more, mainly due to the frequent use of
high-resolution computerized tomography (HRCT) [4,5].
Approximately 40% of patients with AAT deﬁciency have
chronic cough and sputum expectoration [6]. The presence of
bronchiectasis is recognized, but, because studies of the inci-
dence are limited [7–10], it is recognized that further data are
needed to evaluate the frequency and type of bronchiectasis,
and to assess the clinical and physiologic manifestations [11].
There are isolated case reports that have suggested a puta-
tive association between bronchiectasis and AAT deﬁciency in
the absence of emphysema [12,13]. It is well recognized that
AAT deﬁciency is associated with the early development of
emphysema, but only a limited number of studies have as-
sessed the association between AAT deﬁciency and bronchiec-
tasis. The purpose of the current study was to address and
evaluate the frequency of bronchiectasis, and to assess clinical
and physiologic manifestations of these patients.
Material and methods
Patients with non cystic ﬁbrosis bronchiectasis attending to outpa-
tient chest clinicor admitted to theChestDepartment inSohagUni-
versity Hospital were enrolled in the study. The study was of one
year duration andhad approval from theFaculty of scientiﬁc ethics
committee. Written informed consent was taken from all patients.
The patients were subdivided into two groups:
Group A: bronchiectasis with hyperinﬂation. (30 cases)
Group B: bronchiectasis without hyperinﬂation. (30 cases)
These groups of patients were diagnosed by a chest high
resolution computed tomography scan.
Exclusion criteria:
1. Positive reversibility test as improvement of post broncho-
dilator FEV1 more than 12% on pulmonary function test,
2. Cystic ﬁbrosis patients and infected cystic lung,
3. Past history of tuberculosis.
6. Quantitative measurement of alpha-1-antitrypsin level in blood:
All patients of the two groups were subjected to quantitative
measurements of serum level of alpha 1 antitrypsin. 2 ml of whole
blood was taken from the patient in a sterile collection tube, the
specimen sent to lab within 24 h, then central centrifugation done,
Alpha 1 antitrypsin serum level was measured by a radial
immunoassay, the values expressed as milligrams per deciliter.
Reference values between 150 and 350 mg/dl are considered
normal, the values below 150 mg/dl considered deﬁcient [15]
The PI type can be predicted from the serum levels [16]:
PiMM: 100% (normal)
PiMS: 80% of normal serum level of A1AT
PiSS: 60% of normal serum level of A1AT
PiMZ: 60% of normal serum level of A1AT, mild deﬁciency
PiSZ: 40% of normal serum level of A1AT, moderate
deﬁciency
PiZZ: 10–15% (severe alpha 1-antitrypsin deﬁciency)
7. Statistical methods used for data analysis:
The data were subjected to statistical analysis and tabulation
using SPSS version 18. p Value is considered signiﬁcant if less than
0.05 then the results were presented to fulﬁll the objectives of the
study
Table 1 Personal characteristics of patient with bronchiectasis
Total Group A with hy
Age
Mean (SD) 45.93 (13.53) 55 (8.58)
Gender
Female
Males
20 (33.33%)
40 (66.67%)
5 (16.67%)
25 (83.33%)
Smoking history
No
Yes
34 (56.67%)
26 (43.33%)
8 (26.67%)
22 (73.33%)
Smoking type
No
Cigarette
Goza
Mixed
34 (56.67%)
12 (20.00%)
8 (13.33%)
6 (10.00%)
8 (26.67%)
10 (33.33%)
6 (20.00%)
6 (20.00%)
Smoking index
No
Mild
Moderate
Heavy
34 (56.67%)
2 (3.51%)
3 (5.26%)
18 (31.58%)
8 (26.67%)
0
1 (3.70%)
18 (66.67%)
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The study was done at the Chest Department of Sohag Univer-
sity Hospital in year 2011 and included 60 patients categorized
into two groups: group A: included 30 cases of bronchiectasis
with hyperinﬂation, with mean age 50 years (SD: 8.58) of
which 25 cases were males (83.33%), and 22 cases were smok-
ers (73.33%), predominately heavy (66.67%) cigarette smok-
ing (33.33%).
Group B: included 30 cases of bronchiectasis without
hyperinﬂation, with mean age of 36.87 (SD: 11.35), of which
15 cases (50%) were males, and 26 cases (86.67%) were non
smokers.
There was a signiﬁcant difference between the two groups
in age (p = 0.0001). And a signiﬁcant difference is seen in gen-.
perinder distribution (p = 0.006), also in smoking history
(p = 0.0001) (Table 1).
As regards the age of onset, there was a signiﬁcant differ-
ence between the two groups, where group A: 35.83 (SD:
5.63) versus 23.57 (SD: 11.53) for the group B (p = 0.0001).
Almost all patients of both groups showed cough and
expectoration, and 27 cases (90%) of group A showed exer-
tional dyspnea, while 19 cases (63.33%) of the group B showed
exertional dyspnea (Table 2). In the ﬁrst group, the cases who
experienced hemoptysis were 12 (40%) while in the second
group 20 cases (66.67%) experienced hemoptysis, this reﬂects
a signiﬁcant difference between the two groups (p = 0.04).
There was an insigniﬁcant difference in sinusitis, 9 cases
(30%) for the 3rd group, and 5 cases (16.67%) for the 4th
group and there was no signiﬁcant difference in hepatological
symptoms, 2 cases (6.67%) in each group (Table 2).
As regards family history, 2 cases (6.67%) of the group A
showed positive family history, in contrast to 7 cases
(23.33%) of the group B who showed positive family history
(p = 0.07). The general examination, 21 cases (70%) of group
A were cyanosed while only 11 cases (36.33%) in group B were
cyanosed, with a signiﬁcant difference (p= 0.01). There was a
signiﬁcant difference in lower limb edema, 18 cases (60%) in
group A and 7 cases (23.33%) in group B (p= 0.004) with
no signiﬁcant difference as regards clubbing of ﬁngers
(Table 3).
All cases of group A showed signs of hyperinﬂation while
no case in group B showed it, and all cases of group A were
wheezy while 7 cases (23.33%) of the second group were whee-
zy with a signiﬁcant difference (p< 0.001) and almost all pa-
tients of both groups had crepitations on auscultation
(Table 3).
Radiological evaluation of both groups showed, all patients
of group A showed radiological signs of hyperinﬂation and
bronchiectatic changes also all patients of the group B showed
bronchiectatic changes without hyperinﬂation (signiﬁcant dif-
ference in radiological evaluation p< 0.001). In the ﬁrstﬂation Group B without hyperinﬂation P value
36.87 (11.35) <0.0001
15 (50.00%)
15 (50.00%)
0.006
26 (86.67%)
4 (13.33%) <0.0001
26 (86.67%)
2 (6.67%)
2 (6.67%)0
<0.0001
26 (86.67%)
2 (6.67%)
2 (6.67%)
0
<0.0001
Table 3 General and chest examination of patients with
bronchiectasis.
Total Group A Group B P value
General examination
Cyanosis
No
Yes
28 (46.67%)
32 (53.33%)
9 (30.00%)
21 (70.00%)
19 (63.33%)
11 (36.33%)
0.01
Clubbing
No
Yes
36 (60.00%)
24 (40.00%)
15 (50%)
15 (50%)
21 (70.00%)
9 (30.00%)
0.11
LL edema
No
Yes
35 (58.33%)
25 (41.67%)
12 (40.00%)
18 (60.00%)
23 (76.67%)
7 (23.33%)
0.004
Chest examination
Hyperinﬂation
No
Yes
30 (50%)
30 (50%)
0
30 (100.00%)
30(100%)
0
<0.0001
Wheezes
No
Yes
23 (38.33%)
37 (61.67%)
0
30 (100.00%)
23 (76.67%)
7 (23.33%)
<0.0001
Crepitations
No
Yes
0
60 (100.00%)
0
30 (100.00%)
0
30 (100.00%)
Table 2 Symptoms of patient with bronchiectasis.
Total Group A Group B P value
Age of onset
Mean (SD) 29.7 (10.92) 35.83 (5.63) 23.57 (11.53) <0.0001
Cough and expectoration
No
Yes
0
60 (100.00%)
0
30 (100%)
0
30 (100%)
Dyspnea
No
Yes
14 (23.33%)
46 (76.67%)
3 (10%)
27 (90.00%)
11 (36.67%)
19 (63.33%)
0.02
Hemoptysis
No
Yes
28 (46.67%)
32 (53.33%)
18 (60.00%)
12 (40.00%)
10 (33.33%)
20 (66.67%)
0.04
Symptoms of sinusitis
No
Yes
46 (76.67%)
14 (23.33%)
21 (70.00%)
9 (30.00%)
25 (83.33%)
5 (16.67%)
0.22
Hepatological symptoms
No
yes
58 (96.67%)
2(3.33%)
29 (96.67%)
1 (3.33%)
29 (96.67%)
1 (3.33%)
0.37
Family history
No
Yes
51 (85.00%)
9 (15.00%)
28 (93.33%)
2 (6.67%)
23 (76.67%)
7 (23.33%)
0.07
314 M.S. Badawy et al.group, 15 cases had CT chest and showed bilateral bronchiec-
tasis with air trapping in 9 cases (60%) and unilateral bronchi-
ectasis with air trapping in 6 cases (40%). In the second group,
25 patients had CT chest and 15 cases showed bilateral distri-
bution (60%) and 10 cases showed unilateral bronchiectatic
changes (40%).
As regards the pulmonary function tests, showed obstruc-
tive pattern for group A (mean FEV1:29.61, meanFVC:54.47, mean FEV1/FVC:43.68), while were normal for
the group B (mean FEV1:69.65, mean FVC:81.85, mean
FEV1/FVC: 71.47) this means signiﬁcant difference between
the two groups with (P < 0.001) (Table 4). The arterial
blood gases of the group A showed slight hypoxemia and
hypercapnea (mean PO2: 62.4, mean PCO2: 50.29) with near
normal parameters in group B (mean PO2:68.68, mean
PCO2:41.73), with a signiﬁcant difference between the two
groups (Table 4).
The serum level of alpha 1 antitrypsin deﬁciency was
deﬁcient in one case of group A (3.33%) with value 142 mg/
dl (70% normal) and mean level for the group: 190.65 mg/dl
(SD: 27. 28) while in the group B two brother patients were
deﬁcient (values: 86 mg/dl (43% normal), 92 mg/dl (46% nor-
mal), and the mean value of the group was 181.17 (SD: 35.87)
without a signiﬁcant difference between groups (Table 4).
For the deﬁcient group, the mean serum A1AT level was
106.33 (SD: 41.37), while the mean serum A1AT level for the
normal group: 198.46 (SD: 25.34) (Great signiﬁcance value
p< 0.001).
The distribution of deﬁciencies in the two groups was as
follows:
One case (3%) in the 1st group (bronchiectasis with
hyperinﬂation)
Two cases (6%) in the 2nd group (bronchiectasis without
hyperinﬂation).
The values of deﬁciencies were as follows:
One case with partial deﬁciency of values: (142 mg/dl in 1st
group).
Two cases with severe deﬁciency (Serum A1AT level <50%
normal) of values: (86 mg/dl, 92 mg/dl, in the 2nd group of
patients.
Table 4 Pulmonary function tests and bl. gases, serum alpha 1antitrypsin level predicted PI of patients with bronchiectasis.
Total Group A Group B P value
FEV1
Mean (SD)
50.81 (25.72) 29.61 (8.47) 69.65 (20.63) <0.0001
FVC
Mean (SD) 68.96 (21.86) 54.47 (15.07) 81.85 (18.74) <0.0001
FEV1/FVC
Mean (SD) 58.39 (17.91) 43.68 (9.25) 71.47 (12.81) <0.0001
PO2
Mean (SD) 65.70 (13.37) 62.40 (12.59) 68.68 (13.57) 0.08
PCO2
Mean (SD) 45.79 (9.58) 50.29 (8.68) 41.73 (8.59) 0.0004
Alpha 1 antitrypsin
Mean (SD)
185.91 (31.95) 190.65 (27.28) 181.17 (35.87)
0.25
Predicted PI
MM
MS
MZ,SS
SZ
57 (95.00)
0
1 (1.67%)
2 (3.33%)
29 (96.67%)
0
1 (3.33%)
0
28 (93.33%)
0
0
2 (6.67%)
0.22
AATD in non cystic ﬁbrosis bronchiectasis 315Discussion
Bronchiectasis is recognized in a1-antitrypsin (AAT) deﬁciency
but data are little concerning the frequency of bronchiectasis,
as well as the clinical presentations and physiologic manifesta-
tions. Airway disease, including bronchiectasis and changes in
the airway walls, has been identiﬁed in subjects with AAT deﬁ-
ciency, but these studies have been a small case series and lar-
gely limited to general radiographic description [8–10].
Bronchiectasis is a disease state deﬁned by irreversible dilation
of part of the bronchial tree caused by destruction of the mus-
cle and elastic tissue. It is classiﬁed as an obstructive lung dis-
ease. Cylindrical bronchiectasis has been described at autopsy
[16], and there are isolated case reports that have suggested a
putative association between bronchiectasis and AAT deﬁ-
ciency in the absence of emphysema [12,13]. This is consistent
with our ﬁndings as there are two brother cases of moderate
AATD in bronchiectasis patients without evidence of
hyperinﬂation.
Patients with alpha-1 antitrypsin deﬁciency have been
found to be particularly susceptible to bronchiectasis [2].
Approximately one-half of the subjects reported productive
cough on a regular basis, consistent with previous estimates
[7], and those subjects with frequent production of sputum
were found to have more extensive bronchiectasis and bron-
chial wall thickening than were subjects with infrequent spu-
tum production. In comparison with our study all cases had
excessive colored sputum production (suppurative syndrome)
with only 3 cases having low serum level of AATD.
Majority of our patients were symptomatic in adult age as
35 years, 23 years respectively. All the cases complained of
productive cough (suppurative syndrome) and 27 cases (90%
in the 1st group) and 19 (63% in the second group) complained
with dyspnea at the initial evaluation. While 12 (40%) cases in
the 1st group and 20 (67%) cases in the second group were
admitted because of recurrent hemoptysis. Hemoptysis was
established sometimes as the only reason of assessment andmost of the cases were controlled conservatively, this is in
agreement with Mehmet et al. [17].
Chronic respiratory failure is another important complica-
tion leading to increased morbidity and worsening of quality
of life. In a study of 67 patients with more extended bronchi-
ectasis, admitted to ICU because of acute respiratory failure,
25% of the cases had used LTOT previously. The mortality
rate in 1 year was 40% and a previous history of LTOT was
identiﬁed as a predictor for mortality [18]. In our study includ-
ing patients with less extended as well as advanced disease,
CRF was present in 21 (70%) in the 1st group of our patients
and 11 (36%) in the group without hyperinﬂation with the
necessity of LTOT at home, this respiratory failure was ob-
served more in the cystic type of disease.
In this study, COPD and asthma were frequently observed
in patients with bronchiectasis. Asthma or COPD was the co-
morbidity in 23% of the second group and 50% of the 1st
group of our patients, respectively. These rates may give rise
to the thought of non-cystic ﬁbrosis bronchiectasis being more
prevalent than expected as co-morbidity to COPD or asthma
in our population. Bronchiectasis can unfavorably affect the
clinical course of both these diseases by increasing the airway
inﬂammation and bacterial colonization, by increasing the at-
tack severity in COPD [19], and by contributing to severe and
difﬁcult-to-control asthma with pulmonary complications [20].
Therefore, to improve the control of these disorders, bronchi-
ectasis should be considered and investigated as co-morbidity
in certain patients.
In our study a mixed type of pulmonary function was ob-
served in the 1st group of patients while in the second group
a restrictive function was seen and this is similar to other stud-
ies, who stated that mixed type pulmonary function abnormal-
ity was observed more frequently in the cystic type [21].
HRCT scanning is the diagnostic method for our cases with
bronchiectasis. The extent and type of the disease can also be
determined. In nearly 35% of our patients, cystic type was de-
tected predominantly. It was observed that patients with cystic
316 M.S. Badawy et al.type had a worse clinical picture than the others. This is in
accordance with Agarwal [22]. There were 18 cases (60%) in
the 1st group and 7 cases (23%) in the second group who
had decompensated Cor-pulmonale with severe impairment
of respiratory function and this is consistent with Angrill
and Alzeer [23,24] who stated that cystic type bronchiectasis
was stated to increase the bacterial colonization in airways
(especially Pseudomonas), leading to more signiﬁcant worsen-
ing of pulmonary functions and more frequent development
of pulmonary hypertension. Our study revealed two brothers
had low serum A1ATD in bronchiectasis without hyperinﬂa-
tion and most cases of bronchiectasis had no deﬁnite cause
and this is consistent with ATS/ETS guidelines [11] who stated
that features which should prompt suspicion by physicians
that their patient may be more likely to have AAT deﬁciency
include; family history of bronchiectasis, and bronchiectasis
without evident etiology.
In Saudi Arabia 35 cases of bilateral widespread bronchiec-
tasis were surveyed by Al-Kassimi, 1996 (who did not have
cystic ﬁbrosis, tuberculosis, or any known cause for bronchiec-
tasis) and none had alpha1-antitrypsin deﬁciency. The rela-
tively small number of cases reﬂects the rarity of bilateral
bronchiectasis outside the spheres of cystic ﬁbrosis, tuberculo-
sis, or immunoglobulin deﬁciency [25]. Also, Hutchinson et al.,
in the multicenter survey of deﬁcient subjects conducted by the
British Thoracic Society none of the 126 deﬁcient patients or
the 40 deﬁcient relatives had clinical or radiological evidence
of bronchiectasis [26].
Our study is in concordance with Al-Kassimi and Hutchin-
son et al that report, alpha 1 antitrypsin deﬁciency is a rare
cause of bronchiectaisis and possibly found in patients with
bronchiectasis even with concomitant emphysema.
The present data showed that alpha 1 antitrypsin is present
in patients with bronchiectasis either with or without emphy-
sema (3/60). The results of the present study support the gen-
eral concept of targeted screening for AAT deﬁciency in our
country, with a large population of bronchiectasis patients
and low awareness among care-givers about this genetic condi-
tion. The study is done in a single hospital and therefore the
results may not represent the general population but it may
be a nucleus for more extended multicenter study.Conclusion
A1ATD can be found in patients with bronchiectasis and can
be a possible cause in cases with or without concomitant
hyperinﬂation. Inheritance could inﬂuence an individual’s risk
of A1ATD for developing bronchiectasis.
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